Skip to content
All Sections
Subscribe Now
54°F
Friday, June 28th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
54°F
Friday, June 28th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VALNEVA
< Previous
1
2
Next >
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
June 26, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
June 24, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
June 05, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
June 04, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
June 03, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
May 31, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
May 21, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
May 13, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 07, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
March 26, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
March 25, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
March 21, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
March 20, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
March 18, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
March 04, 2024
From
VALNEVA
Via
GlobeNewswire
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
February 29, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
February 15, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Sale of Priority Review Voucher for $103 Million
February 05, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
January 10, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
January 04, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Provides Updated 2023 Financial Guidance
December 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
December 20, 2023
From
VALNEVA
Via
GlobeNewswire
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
November 27, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
November 15, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
November 13, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
November 10, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
November 07, 2023
From
VALNEVA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close